Targeted Delivery of Sunitinib by MUC-1 Aptamer-Capped Magnetic Mesoporous Silica Nanoparticles

Targeted Delivery of Sunitinib by MUC-1 Aptamer-Capped Magnetic Mesoporous Silica Nanoparticles

Magnetic mesoporous silica nanoparticles (MMSNPs) are being widely investigated as multifunctional novel drug delivery systems (DDSs) and play an important role in targeted therapy. Here, magnetic cores were synthesized using the thermal decomposition method. Further, to improve the biocompatibility...

Full description

Bibliographic Details
Main Authors:	Mitra Torabi, Ayuob Aghanejad, Pouria Savadi, Abolfazl Barzegari, Yadollah Omidi, Jaleh Barar
Format:	Article
Language:	English
Published:	MDPI AG 2023-01-01
Series:	Molecules
Subjects:	sunitinib ovarian cancer targeted drug delivery anti-mucin 1 aptamer magnetic mesoporous silica nanoparticles
Online Access:	https://www.mdpi.com/1420-3049/28/1/411

Similar Items

Fabrication of mesoporous silica nanoparticles for targeted delivery of sunitinib to ovarian cancer cells
by: Mitra Torabi, et al.
Published: (2023-05-01)

A Simple Aptamer SERS Sensor Based on Mesoporous Silica for the Detection of Chlorpyrifos
by: Sa Dong, et al.
Published: (2022-10-01)

Potential for use sunitinib in pancreatic neuroendocrine tumors
by: A. A. Markovich, et al.
Published: (2019-06-01)

Photochemically-Induced Release of Lysosomal Sequestered Sunitinib: Obstacles for Therapeutic Efficacy
by: Judith Jing Wen Wong, et al.
Published: (2020-02-01)

Aptamer-Gated Mesoporous Silica Nanoparticles for N Protein Triggered Release of Remdesivir and Treatment of Novel Coronavirus (2019-nCoV)
by: Xiaohui Zhang, et al.
Published: (2022-11-01)

Sunitinib for adenocarcinoma of the rete testis: a case report
by: Kezhen Li, et al.
Published: (2024-04-01)

Sunitinib in pancreatic neuroendocrine tumors. Clinical case
by: A. A. Markovich, et al.
Published: (2019-12-01)

SIDE EFFECTS OF SUNITINIB MANIFESTED ON SKIN OF PATIENTS DIAGNOSED WITH RENAL CELL CARCINOMA: CASE-CONTROL STUDY
by: Bojana Petrović, et al.
Published: (2009-10-01)

Biological Role of Pazopanib and Sunitinib Aldehyde Derivatives in Drug-Induced Liver Injury
by: Maud Maillard, et al.
Published: (2022-09-01)

Leukocytoclastic Vasculitis after Long-Term Treatment with Sunitinib: A Case Report
by: Alexandra Karadimou, et al.
Published: (2011-08-01)

Sunitinib efficacy with minimal toxicity in patient-derived retinoblastoma organoids
by: Atthapol Srimongkol, et al.
Published: (2023-02-01)

The Impact of Modifying Sunitinib Treatment Scheduling on Renal Cancer Tumor Biology and Resistance
by: Harrison Sicheng Lin, et al.
Published: (2022-01-01)

Transgelin Contributes to a Poor Response of Metastatic Renal Cell Carcinoma to Sunitinib Treatment
by: Pavla Bouchalova, et al.
Published: (2021-09-01)

Sunitinib induced hepatotoxicity in L02 cells via ROS-MAPKs signaling pathway
by: Ting-Li Tang, et al.
Published: (2022-10-01)

Sunitinib-Induced Elevation of Mean Corpuscular Volume (MCV)—Exploring Its Possible Clinical Relevance in Cancer Patients
by: Michal Rihacek, et al.
Published: (2022-06-01)

Heightened JNK Activation and Reduced XIAP Levels Promote TRAIL and Sunitinib-Mediated Apoptosis in Colon Cancer Models
by: Devalingam Mahalingam, et al.
Published: (2019-06-01)

An Interesting Case: Sunitinib-Induced Microangiopathic Hemolytic Anemia and Nephrotic Syndrome
by: Veysel Haksöyler, et al.
Published: (2021-06-01)

Aptamers and Cancer
by: Nasrin Yazdanpanahi, et al.
Published: (2016-04-01)

Pharmacokinetics and bioequivalence of sunitinib and Sutent® in Chinese healthy subjects: an open-label, randomized, crossover study
by: Yanli Wang, et al.
Published: (2023-11-01)

The Efficacy of Sunitinib Treatment of Renal Cancer Cells Is Associated with the Protein PHAX In Vitro
by: Rafia S. Al-Lamki, et al.
Published: (2020-04-01)

Sunitinib and Pterostilbene Combination Treatment Exerts Antitumor Effects in Gastric Cancer via Suppression of PDZD8
by: Yudai Hojo, et al.
Published: (2022-04-01)

Síndrome nefrótico como manifestación de microangiopatía trombótica secundaria al uso crónico de sunitinib
by: John Fredy Nieto-Ríos, et al.
Published: (2022-11-01)

High-Dose Intermittent Treatment with the Multikinase Inhibitor Sunitinib Leads to High Intra-Tumor Drug Exposure in Patients with Advanced Solid Tumors
by: Sophie L. Gerritse, et al.
Published: (2022-12-01)

The yin yang of sunitinib: One drug, two doses, and multiple outcomes
by: Mohamed Elgendy
Published: (2017-03-01)

Phosphoproteomic Analysis Identifies TYRO3 as a Mediator of Sunitinib Resistance in Metastatic Thymomas
by: Stefan Küffer, et al.
Published: (2022-09-01)

Nephrotic syndrome as a manifestation of thrombotic microangiopathy due to long-term use of sunitinib
by: John Fredy Nieto-Ríos, et al.
Published: (2022-11-01)

Epigenome screening highlights that JMJD6 confers an epigenetic vulnerability and mediates sunitinib sensitivity in renal cell carcinoma
by: Chuanjie Zhang, et al.
Published: (2021-02-01)

Sunitinib potentiates the cytotoxic effect of electrochemotherapy in pancreatic carcinoma cells
by: Bosnjak Masa, et al.
Published: (2022-03-01)

Catfish Egg Lectin Enhances the Cytotoxicity of Sunitinib on Gb3-Expressing Renal Cancer Cells
by: Jun Ito, et al.
Published: (2023-08-01)

Synthesis and Characterization of Novel Copper(II)-Sunitinib Complex: Molecular Docking, DFT Studies, Hirshfeld Analysis and Cytotoxicity Studies
by: Facundo Tarasi, et al.
Published: (2021-12-01)

Astragaloside IV attenuates sunitinib-associated cardiotoxicity by inhibiting COUP-TFII
by: Wanting Qin, et al.
Published: (2024-02-01)

Role of Sam68 in Sunitinib induced renal cell carcinoma apoptosis
by: Zeshen Wu, et al.
Published: (2022-10-01)

Multifunctional Nanoplatform Based on Sunitinib for Synergistic Phototherapy and Molecular Targeted Therapy of Hepatocellular Carcinoma
by: Wenjing Xu, et al.
Published: (2023-03-01)

Acute acalculous cholecystitis in a patient with metastatic renal cell carcinoma treated with sunitinib
by: Leonardo Gomes da Fonseca, et al.
Published: (2014-04-01)

Sunitinib in Metastatic Renal Cell Carcinoma: The Pharmacological Basis of the Alternative 2/1 Schedule
by: Antonello Di Paolo, et al.
Published: (2017-08-01)

Case report of a renal cell carcinoma patient with acute pancreatitis under both sunitinib and axitinib treatment
by: Utku Oflazoglu, et al.
Published: (2016-08-01)

Current Perspectives on Aptamers as Diagnostic Tools and Therapeutic Agents
by: Prabir Kumar Kulabhusan, et al.
Published: (2020-07-01)

LPPR5 Expression in Glioma Affects Growth, Vascular Architecture, and Sunitinib Resistance
by: Lena Stange, et al.
Published: (2022-03-01)

Combined Ibuprofen-Nanoconjugate Micelles with E-Selectin for Effective Sunitinib Anticancer Therapy
by: Zeng X, et al.
Published: (2022-12-01)

Osteonecrosis of the jaws in patient received bisphosphonates and sunitinib separately: A case report
by: Farzaneh Ashrafi, et al.
Published: (2017-01-01)